2,057 Shares in Repligen Co. (NASDAQ:RGEN) Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the third quarter, Holdings Channel reports. The firm purchased 2,057 shares of the biotechnology company’s stock, valued at approximately $306,000.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Repligen by 0.4% during the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after purchasing an additional 21,719 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after buying an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC grew its stake in shares of Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after buying an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after buying an additional 425,061 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in shares of Repligen by 14.4% during the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after buying an additional 71,274 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on RGEN shares. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research note on Monday, August 5th. JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Wolfe Research initiated coverage on Repligen in a research note on Thursday. They issued a “peer perform” rating on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Finally, Wells Fargo & Company initiated coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Price Performance

RGEN stock opened at $124.73 on Monday. The firm has a 50 day moving average price of $141.09 and a 200-day moving average price of $144.34. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The firm has a market capitalization of $6.99 billion, a price-to-earnings ratio of -337.10, a PEG ratio of 3.43 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the business earned $0.23 earnings per share. The business’s revenue was up 9.7% on a year-over-year basis. Equities research analysts forecast that Repligen Co. will post 1.52 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.